

NATURAL HISTORY AND PATHOGENESIS OF TAKOTSUBO CARDIOMYOPATHY

Kuljit Singh

*Thesis submitted for the degree of
Doctor of Philosophy
In
Medicine
At
The University of Adelaide
(Faculty of Health Sciences)*

Department of Cardiology

**The Queen Elizabeth Hospital
SA Australia 5011**

Declaration

This thesis is the result of my own investigation, except where otherwise stated. It contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. In addition, I certify that no part of this work will, in future, be used in a submission for any other degree or diploma in any university or other tertiary institution without the prior approval of the University of Adelaide and where applicable, any partner institution responsible for the joint-award of this degree.

I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968. The author acknowledges that copyright of published works contained within this thesis resides with the copyright holder(s) of these works.

I also give permission for the digital version of my thesis to be made available on the web, via the university's digital research repository, the Library catalogue, and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

.....

Kuljit Singh (9.2.2015)

Acknowledgements

I would like to express my appreciation and gratitude to my supervisor, Professor John David Horowitz; you have been a tremendous mentor for me. I would like to thank you for encouraging my research and for allowing me to grow as a researcher. I am truly indebted and thankful to you for your help in generating ideas and for your support and guidance throughout. I would also like to acknowledge Dr. Yuliy Chirkov, who, as well as co-supervising this project, took a leading role among all the scientists at the Basil Hetzel Institute to teach me basic research procedures.

My colleagues, Dr. Christopher Neil, Ms. Irene Stafford, Dr. Thanh Ha Nguyen, Ms. Jeanette Stansborough and Ms. Kristin Carson have all been of great assistance in the TTC project, with both intellectual contributions as well as involvement in the day-to-day work of the study.

This thesis relied heavily on the basic research techniques: in this regards, notable thanks go to Dr. Giovanni Licari. Without his guidance and assistance in the basic laboratory work this thesis would not have been possible. In addition, I would like to acknowledge the help of Mr. Matthew Chapman for his help in human and animal cardiac imaging.

I would like to thank the National Health and Medical Research Council for funding this work and, similarly, the generosity of numerous patients and controls in giving their time for the studies described herein.

Finally, I would like to thank my wife Upinder Kaur Bhalla and my mother Amarjit Kaur for their support, patience and understanding.

Statement of contribution to research

The studies were conceived and designed jointly by Professor John Horowitz and myself.

Execution

I performed all the recruitment and organization of patients into the studies, with the assistance of Ms. Jeanette Stansborough (research nurse). I collected all the clinical data with assistance from Ms. Stansborough. I performed all the data search and meta-analysis with the assistance of Ms. Kristen Carson. I analysed of the echocardiographic studies for humans and animals. Some of the immunohistochemistry studies, in particular detection of apoptosis (TUNEL staining), Poly ADP ribose (PAR Staining) were performed by me. I also performed platelet aggregometry on new patients diagnosed with TTC between 2012 and 2014. Dr. Giovanni Licari performed immunohistochemistry studies of measurement of 3-nitrotyrosine and TXNIP. I performed quantification of staining for 3-nitrotyrosine and TXNIP with the assistance of Dr. Giovanni Licari. I performed quantification of staining for apoptosis, and inter-observer analysis were performed with Dr. Betty Raman. Plasma 3-Nitrotyrosine levels were analyzed in Prof. Tsikas's laboratory in Hannover, Germany.

Analysis

All the data were collated and analyzed by myself.

List of published studies

1. Kuljit Singh, Kristin Carson, Zafar Usmani, Gagandeep Sawhney, John Horowitz: Systematic Review and Meta-Analysis of Incidence and Correlates of Recurrence of Takotsubo Cardiomyopathy. *International Journal of Cardiology* 04/2014; 174(3):696-701
2. Kuljit Singh, Kristin Carson, Ranjit Shah, Gagandeep Sawhney, Balwinder Singh, Ajay Parsaik, Harel Gilutz, Zafar Usmani, John Horowitz: Meta-Analysis of Clinical Correlates of Acute Mortality in Takotsubo Cardiomyopathy. *The American journal of cardiology* 04/2014; 113(8):1420-1428.
3. Kuljit Singh, Christopher Neil, Thanh Nguyen, Jeanette Stansborough, Cherin Chong, Dana Dawson, Micheal Frenneaux, John Horowitz. Dissociation of early shock in Takotsubo cardiomyopathy from either right or left ventricular systolic dysfunction. *Heart Lung and Circulation*. 12/2014; 23(12):1141-8
4. Betty Raman, Kuljit Singh, Christopher J Zeitz, John D Horowitz: Takotsubo cardiomyopathy presenting as S-T elevation myocardial infarction: Not gone but forgotten? *International Journal of Cardiology*. 01/2014; 172(1):e261-2
5. Kuljit Singh, Tina Marinelli, John D Horowitz: Takotsubo cardiomyopathy after anti-influenza vaccination: catecholaminergic effects of immune system. *The American journal of emergency medicine* 07/2013; 31(11): 1627.

Table of Contents

Declaration	3
Acknowledgements	5
Statement of contribution to research	7
List of published studies	9
List of figures	15
Abstract	20
1 Chapter: Literature review	22
<i>1.1 Cardiac cell death</i>	<i>23</i>
1.1.1 Cell death	23
1.1.2 Cardiac cell death.....	24
<i>1.2 Evolution of cardiovascular medicine: From acute myocardial infarction to Takotsubo Cardiomyopathy</i>	<i>24</i>
<i>1.3 Takotsubo cardiomyopathy</i>	<i>25</i>
1.3.1 History	27
1.3.1.1 The problem of historical definition and diagnosis.	29
1.3.1.2 Evolving views regarding diagnostic algorithms	30
1.3.2 Epidemiology	33
1.3.2.1 Incidence and prevalence.....	33
1.3.2.2 Age of onset	34
1.3.3 Clinical characteristics.....	35
1.3.3.1 Antecedent psychological stress in TTC	35
1.3.3.2 Medical and surgical illness.....	35
1.3.3.3 Association of cancer with TTC.....	36
1.3.3.4 Symptom onset.....	37
1.3.4 Electrocardiographic, biochemical and imaging abnormalities.....	37
1.3.4.1 Electrocardiographic changes	37
1.3.4.2 Biochemical markers.....	38
1.3.4.3 Echocardiographic changes	45
1.3.4.4 Cardiac magnetic resonance imaging	49
1.3.5 Pathogenesis.....	52
1.3.5.1 TTC as ischemia	52
1.3.5.2 Role of interaction between catecholamines and myocardium in the pathogenesis of TTC ...	56
1.3.6 Natural history.....	68
1.3.6.1 The acute phase issues.....	68
1.3.6.2 Long term outcome- incomplete recovery and problem of recurrence.....	71
2 Chapter: Pathogenesis of Takotsubo Cardiomyopathy-Animal work	74
2.1 Introduction.....	75
2.2 Methodology.....	78
2.2.1 Development of rat model of TTC	78

2.2.2	Echocardiographic analysis	12
2.2.2	Echocardiographic analysis	79
2.2.3	Immunohistochemical studies.....	81
2.2.3.1	3Nitrotyrosine, TXNIP and PAR staining	82
2.2.3.2	TUNEL staining	83
2.2.4	Quantification of staining.....	84
2.2.4.1	3NT and TXNIP staining quantification	84
2.2.4.2	TUNEL staining quantification	85
2.2.4.3	PAR staining quantification.....	86
2.3	<i>Statistical analysis</i>	87
2.3.1	Effects of Isoprenaline.....	87
2.3.2	Effects of 3AB.....	87
2.4	<i>Results</i>	87
2.4.1	Induction of TTC.....	88
2.4.1.1	Echocardiographic analysis	90
2.4.1.2	Histological/immunohistological evaluation	93
2.4.2	Modulation of TTC: effects of 3AB	96
2.4.2.1	Echocardiographic analysis	96
2.4.2.2	Immunohistochemistry results.....	99
2.4.3	Discussion.....	101
3	Chapter: Pathogenesis of Takotsubo Cardiomyopathy- Human experiments.....	107
3.1	<i>Introduction</i>	108
3.2	<i>Methods</i>	109
3.2.1	Plasma 3NT concentration	110
3.2.2	Post-mortem studies in TTC patients	110
3.2.3	Statistical methods.....	111
3.3	<i>Results</i>	111
3.3.1	Evaluation of plasma 3-NT concentrations	111
3.3.1.1	Clinical characteristics.....	111
3.3.2	Plasma 3NT comparison.....	113
3.3.3	Post mortem studies.....	116
3.4	<i>Discussion</i>	120
4	Chapter: Implications of right ventricular involvement in Takotsubo cardiomyopathy.....	122
4.1	<i>Introduction</i>	123
4.2	<i>Methods</i>	125
4.2.1	Statistical methods.....	127
4.3	<i>Results</i>	127
4.3.1	Overall basic characteristics	128
4.3.2	RV involvement predicts greater LV injury.....	129
4.3.3	RV involvement is a univariate correlate of hypotension, shock and PHS	130

4.3.4	RV involvement predicts more extensive LV involvement, but is not a multivariate correlate of hypotension, shock or PHS	134
4.4	<i>Discussion</i>	135
4.5	<i>Study limitations</i>	138
4.6	<i>Conclusions</i>	138
5	Chapter: Meta-Analysis and systematic review of clinical correlates of acute mortality in Takotsubo cardiomyopathy	139
5.1	<i>Introduction</i>	140
5.2	<i>Methods</i>	142
5.2.1	Study eligibility.....	142
5.2.2	“Primary” vs. “secondary” TTC.....	142
5.2.3	Data Sources and search strategy.....	142
5.2.4	Study selection and data extraction.....	143
5.2.5	Quality assessment.....	143
5.2.6	Statistical analysis.....	143
5.3	<i>Results</i>	146
5.3.1	Literature identification.....	146
5.3.2	Basic characteristics.....	146
5.3.3	Mortality.....	147
5.3.3.1	Overall	147
5.3.3.2	Clinical correlates of mortality rates.....	148
5.3.3.3	“Primary” vs. “secondary” TTC.....	148
5.3.3.4	Gender differences.....	149
5.3.3.5	Advanced age	151
5.3.3.6	Catecholamine use	152
5.3.4	Complications.....	152
5.3.5	Quality assessment.....	153
5.4	<i>Discussion</i>	156
6	Chapter: A meta-analysis of recurrence of Takotsubo Cardiomyopathy.....	167
7.1	<i>Introduction</i>	168
7.2	<i>Methods</i>	169
7.2.1	Inclusion criteria	169
7.2.2	Search strategy.....	169
7.2.3	Statistical analyses	170
7.3	<i>Results</i>	171
7.4	<i>Discussion</i>	177
8	Summary and future perspectives.....	186
8.1	<i>Summary: major findings</i>	187
8.2	<i>Mechanistic issues</i>	188
8.2.1	Key findings.....	188

8.2.2 Residual issues.....	14
8.2.2 Residual issues.....	189
8.3 <i>Clinical issues</i>	190
8.3.1 Key findings.....	191
8.3.2 Residual issues.....	192
References	195

List of figures

Figure 1: Left ventricular in Takotsubo cardiomyopathy, mimicking the appearance of an “octopus trap”	26
Figure 2: Electrocardiogram of a patient diagnosed with Takotsubo cardiomyopathy showing presence of T wave inversion in all the 12 leads.....	31
Figure 3: Cardiac MRI showing presence of apical odema in a patient diagnosed with Takotsubo Cardiomyopathy.	51
Figure 4: Molecular mechanisms of peroxynitrite mediate cell death.	65
Figure 5: Postulated NO signaling cascade with possible sites for intervention.	66
Figure 6: Radial strain at different time intervals post 5 mg/Kg of Isoprenaline.	78
Figure 7: Analysis of rodent left ventricular apical strain post Isoprenaline	80
Figure 8: Reduction in left ventricular apical strain 24 hours post.....	90
Figure 9: Apical, mid-ventricular and basal left ventricular fractional area shortening at baseline and 24 hours post-isoprenaline.....	92
Figure 10: Mean data for TUNEL content in the apical and basal myocardial sections from control rats (blue) and those treated with isoprenaline (red). P = NS, Bonferroni post hoc correction for apex and base.....	94
Figure 11: Mean data for 3 nitrotyrosine content in the apical and basal myocardial sections from control rats (red) and those treated with isoprenaline (blue).	95
Figure 12: Mean data for TXNIP content in apical and basal myocardial sections from control rats and those treated with isoprenaline. Data are represented as % of the microscopic field.	96
Figure 13: Mean data for LV apical strain at baseline and after treatment with isoprenaline in rats with and without pre-treatment with 3 aminobenzamide.	98
Figure 14: Mean data for apical fractional area shortening at baseline and after treatment with isoprenaline in rats with and without pre-treatment with 3 aminobenzamide.....	98
Figure 15: Mean data for 3 nitrotyrosine percentage staining at left ventricular apex and base after treatment with isoprenaline in rats with and without pre-treatment with 3 aminobenzamide.	99

Figure 16 Mean data for TXNIP percentage staining at left ventricular apex and base after treatment with isoprenaline in rats with and without pre-treatment with 3 aminobenzamide.	100
Figure 17: Mean data for TUNEL stain percentage (quantification of apoptosis) at left ventricular apex and base following isoprenaline treatment with and without 3 aminobenzamide pretreatment.....	101
Figure 18: Plasma 3-NT concentrations in Takotsubo cardiomyopathy patients (TTC) and age-matched controls (C). There was no significant difference between the groups.	114
Figure 19: Concentration of 3NT at the LV apex and base of TTC patients and control.....	118
Figure 27: Pooled analysis with RD and 95% CI comparing acute mortality in primary and secondary TTC groups.	149
Figure 28: Pooled analysis with OR and 95% CI comparing acute mortality in males and females diagnosed with TTC.	151
Figure 29: Pooled analysis with RD and 95% CI comparing acute mortality in males and females diagnosed with TTC.	151
Figure 30: Risk of bias assessment presenting review author’s judgments about each quality criterion presented as a percentage across all included studies. Criteria were based on an adaption of the categories reported in the Tooth et.al. 2005 paper ‘Quality of reporting of observational longitudinal research’.....	154
Figure 31 Risk of bias summary with review author’s judgments about each quality criterion for each included study. Criteria were based on an adaption of the categories reported in the Tooth et.al. 2005 paper ‘Quality of reporting of observational longitudinal research’.....	155
Figure 32: Schematic presentation of literature search and identification of studies.....	172
Figure 33: Adjusted rate of recurrence per 100 patients per year among the studies included in the systematic review (Shown in percentage).	174
Figure 34: Accumulative incidence of recurrence of Takotsubo cardiomyopathy at 6-month intervals.....	175

Figure 35: The graph showing correlation of percentage of patients discharged on β -adrenergic blockers with incidence of recurrence. Each dot represents a separate study. ($R = -0.207, P = 0.28$)..... 176

Figure 36: The graph showing correlation of percentage of patients discharged on angiotensin converting enzyme inhibitor and angiotensin receptor blockers (ACE/ARB) with incidence of recurrence. Each dot represents a separate study. ($R = -0.448, P = 0.016$) 177

Figure 37: Detailed risk of bias assessment showing review authors judgement about each risk of bias item for each included study (red = high risk of bias, green = low risk and yellow = not applicable or unclear risk)..... 179

Figure 38: Risk of bias graph containing review author’s judgment about each risk of bias item presented as a percentage across all included studies (red = high risk of bias, green = low risk and yellow = not applicable or unclear risk)...... 180

List of Abbreviations

AMI	Acute myocardial infarction
ACS	Acute coronary syndrome
ACE	Angiotensin converting enzyme
ADMA	Asymmetric dimethyl arginine
ARB	Angiotensin receptor blocker
BNP; NT-proBNP	B-type natriuretic peptide; amino-terminal prohormone of BNP
cGMP	Cyclic guanosine monophosphate
CA	Coronary angiogram
CMR	Cardiac magnetic resonance imaging
CVA	Cerebrovascular accident
ECG	Electrocardiogram
TOE	Transesophageal echocardiography
TTE	Transthoracic echocardiography
TTC	Takotsubo cardiomyopathy
LAD	Left anterior descending artery
LGE	Late gadolinium enhancement
LOS	Length of stay
LVEF	Left ventricular ejection fraction
LVSV	Left ventricular stroke volume
LVOT	Left ventricular outflow tract
LV	Left ventricle
MR	Mitral regurgitation
MRS	Magnetic resonance spectroscopy
NOS	Nitric oxide synthase
NSTEMI	Non-ST elevation myocardial infarction
PASP	Pulmonary artery systolic pressure
PAR	Poly (ADP) ribose
PARP	Poly (ADP) ribose polymerase
PCWP	Pulmonary capillary wedge pressure
PHS	Prolonged hospital stay
RV	Right ventricle
SAH	Subarachnoid hemorrhage
STEMI	ST elevation myocardial infarction
TXNIP	Thioredoxin interacting protein

VT	Ventricular tachycardia
VF	Ventricular fibrillation
WMSI	Wall motion score index
3NT	3-Nitrotyrosine
3AB	3-Aminobenzamide

Abstract

Introduction: Takotsubo cardiomyopathy (TTC) is a transient left ventricular (LV) systolic dysfunction of uncertain pathogenesis, which occurs predominantly in ageing women. Although there is considerable uncertainty about the pathogenesis of TTC, pronounced catecholamine release and an acute inflammatory process is implicated. Furthermore, natural history of TTC is unknown and correlates of acute complications and incomplete recovery have not been evaluated.

Methods: In the 5 experimental chapters, this thesis examines aspects of (a) pathogenesis and (b) natural history of TTC. As regard the pathogenesis, we hypothesized that increased release of nitric oxide (NO) in patients with TTC potentially induces the formation of peroxynitrite (ONOO⁻) anion with associated redox stress, protein nitration and downstream activation of thioredoxin interacting protein (TXNIP). Evaluation of presence of nitrosative stress was performed in a rat model of TTC in parallel with human experiments looking at the local and systemic rise in the 3-nitrotyrosine (3-NT) as a footmark of ONOO⁻ formation. As a part of clinical investigations, we evaluated the role of RV involvement in early hemodynamic derangement. We performed a meta-analysis to assess the impact of “secondary” TTC, male gender, advancing age and catecholamine use on mortality in TTC. We used a similar approach to assess the correlates of recurrence rate of TTC.

Results:

A. **Pathogenesis:** In rat model of TTC, there was substantially increased myocardial 3-NT (2.9 ± 0.6 % and 0.3 ± 0.1 %; $p < 0.01$) and TXNIP content (16.5 ± 5.2 vs 0.5 ± 0.2 %; $p < 0.01$). Furthermore, use of poly (ADP) ribose polymerase (PARP)-1 inhibitor attenuated the isoprenaline induced LV systolic dysfunction. In human experiments, plasma concentrations of 3-NT did not differ significantly between TTC (2.26 ± 0.22 nmol/L) and control subjects (2.20 ± 0.25 nmol/L). However, myocardial 3-NT and TxNIP content

were increased 4-fold and 10-fold respectively. Furthermore, myocardial content for poly (ADP) ribose (PAR) activity was increased 4 folds.

B. Clinical investigations: RV involvement occurred in 1/3rd of TTC patients. Hypotension was noted in 21% of TTC patients, while shock occurred in 16%. RV involvement was a univariate but not a multivariate correlate of either hypotension or shock and did not result in prolonged hospital stay. RV involvement predicted more extensive LV hypokinesis and LV systolic dysfunction.

C. Meta-Analysis: In-hospital mortality among patients with TTC was 4.5% (95% CI, 3.1%-6.2%). Male gender was associated with higher mortality (OR 2.6, 95% CI, 1.5-4.6, p=0.0008) so was “secondary” TTC (RD-0.11, 95%CI; -0.18 to -0.04, p=0.003).

TTC had 1-2% annual recurrence rate, which was independent of clinic utilization of beta-blocker prescription, but inversely correlated ($r = -0.45$, $p = 0.016$) with ACEi/ARB prescription. Patients with severe TTC at index admission were noted to have more recurrences.

Conclusion:

- A. TTC is associated with evidence of nitrosative stress within left ventricular myocardium.
- B. RV involvement is not an independent predictor of hemodynamic derangement.
- C. Male gender and “secondary” TTC are associated with higher mortality and use of ACEi might reduce recurrence rate.